Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double UCB with IL-2 for Refractory AML
NCT01464359Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2011
- Primary completion
- Oct 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started Oct 2011; status: terminated.
02
Drugs
aldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01464359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01464359.